Medium-term systemic blood pressure after stenting of aortic coarctation: a systematic review and meta-analysis.

aortic coarctation endovascular procedures for aortic and vascular disease hypertension meta-analysis

Journal

Heart (British Cardiac Society)
ISSN: 1468-201X
Titre abrégé: Heart
Pays: England
ID NLM: 9602087

Informations de publication

Date de publication:
10 2019
Historique:
received: 22 02 2019
revised: 27 06 2019
accepted: 01 07 2019
pubmed: 19 7 2019
medline: 9 6 2020
entrez: 19 7 2019
Statut: ppublish

Résumé

Long-term prognosis of patients with coarctation of the aorta (CoA) is impaired due to the high prevalence of hypertension and consequent cardiovascular complications. Although stent implantation results in acute anatomical and haemodynamic benefit, limited evidence exists regarding the late clinical outcome. In this meta-analysis, we aimed to evaluate the medium-term effect of stent placement for CoA on systemic blood pressure (BP). PubMed, EMBASE and Cochrane databases were searched for non-randomised cohort studies addressing systemic BP ≥12 months following CoA stenting. Meta-analysis was performed on the change in BP from baseline to last follow-up using a random-effects model. Subgroup analyses and meta-regression were conducted to identify sources of heterogeneity between studies. Twenty-six studies with a total of 1157 patients and a median follow-up of 26 months were included for final analysis. Meta-analysis showed a 20.3 mm Hg (95% CI 16.4 to 24.1 mm Hg; p<0.00001) reduction in systolic BP and an 8.2 mm Hg (12 studies; 95% CI 5.2 to 11.3 mm Hg; p<0.00001) reduction in diastolic BP. A concomitant decrease in the use of antihypertensive medication was observed. High systolic BP and peak systolic gradient at baseline and stenting of native CoA were associated with a greater reduction in systolic BP at follow-up. Stent implantation for CoA is associated with a significant decline in systolic and diastolic BP during medium-term follow-up. The degree of BP reduction appears to be dependent on baseline systolic BP, baseline peak systolic gradient, and whether stenting is performed for native or recurrent CoA.

Identifiants

pubmed: 31315937
pii: heartjnl-2019-314965
doi: 10.1136/heartjnl-2019-314965
doi:

Types de publication

Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1464-1470

Commentaires et corrections

Type : CommentIn

Informations de copyright

© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Timion A Meijs (TA)

Department of Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands.

Evangeline G Warmerdam (EG)

Department of Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands.

Martijn G Slieker (MG)

Department of Pediatric Cardiology, Wilhelmina Children's Hospital, Utrecht, The Netherlands.

Gregor J Krings (GJ)

Department of Pediatric Cardiology, Wilhelmina Children's Hospital, Utrecht, The Netherlands.

Mirella M C Molenschot (MMC)

Department of Pediatric Cardiology, Wilhelmina Children's Hospital, Utrecht, The Netherlands.

Folkert J Meijboom (FJ)

Department of Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands.

Gertjan T Sieswerda (GT)

Department of Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands.

Pieter A Doevendans (PA)

Department of Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands.
Netherlands Heart Institute, Utrecht, The Netherlands.

Berto J Bouma (BJ)

Department of Cardiology, Academic Medical Center, Amsterdam, The Netherlands.

Robbert J de Winter (RJ)

Department of Cardiology, Academic Medical Center, Amsterdam, The Netherlands.

Barbara J M Mulder (BJM)

Department of Cardiology, Academic Medical Center, Amsterdam, The Netherlands.

Michiel Voskuil (M)

Department of Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH